期刊文献+

多元贝叶斯回归模型框架下绘制成本-效果可接受曲线 被引量:3

Cost-effectiveness Acceptability Curve Drawn from Multivariate Bayesian Regression Model Framework
原文传递
导出
摘要 目的:探讨成本-效果可接受曲线(CEAC)采用贝叶斯方法的原因,以及如何在贝叶斯回归模型框架下绘制CEAC。方法:首先从原理上分析贝叶斯方法的优势,其次在R软件中生成模拟数据并在Openbugs软件中实现模型,绘制CEAC,比较不同先验信息下该曲线的差异。结果:在强先验信息下,参数后验分布的均数比弱先验信息下更准确、标准差更小。在一定范围内,强先验信息下增量-净效益大于0的概率大于弱先验信息下的概率。结论:贝叶斯方法在参数估计、区间估计、概率解释上具有优势。在贝叶斯方法下,CEAC可得到合理的解释。贝叶斯方法先验信息对参数估计与成本-效果分析决策甚为重要。在强先验信息下,参数估计的准确度、变异度更小,同时CEAC也更准确。 OBJECTIVE: To investigate the reasons for cost-effectiveness acceptability curve (CEAC) using Bayesian methods, and how to draw CEAC in the framework of the Bayesian regression model. METHODS: Firstly, the advantages of Bayesian approach were analyzed fi-om the principle. Secondly, R generated simulation data, Openbugs software implemented model and CEAC was drawn. The differences in the curves of different prior information were compared. RESULTS: Under strong prior information,the posterior distribution of the mean parameters was more accurate than weak prior infbrmation, and its standard deviation was smaller than weak prior intbrmation. The probability of incremental-net benefit which was greater than 0 under strong prior was greater than the probability of weak prior within limits. CONCLUSIONS: Bayesian method is characterized with the advantages of parameter estimation, interval estimation and probabilistic interpretation. By Bayesian approach, CEAC can provide a reasonable explanation.The Bayesian approach prior information is important for parameter estimation and cost-effectiveness analysis decision-making. Under strong prior information, the accuracy and variability of the parameter estimation become weak, while CEAC is more accurate.
作者 彭娟 骆福添
出处 《中国药房》 CAS CSCD 2013年第10期865-867,共3页 China Pharmacy
基金 卫生部科技专项课题资助项目(No.2008ZX09312002-003)
关键词 贝叶斯回归 成本-效果 增量-净效益 模拟 Bayesian regression Cost-effectiveness incremental-net benefits Stimulation
  • 相关文献

参考文献7

二级参考文献16

  • 1孙利华,田雪莹.利用药物经济学指导药品定价——完善药品定价方法[J].中国药房,2004,15(9):545-546. 被引量:33
  • 2Fenwick E, Byford S. A guide to cost-effectiveness accept- ability curves [J] .Br J Psychiatry, 2005,187 (8) : 106.
  • 3Sendi PP, Craig BA, Meier G, et al. Cost-effectiveness of azithromyein for preventing Mycobacterium avium com- plex infection in HIV-positive patients in the era of highly active antiretroviral therapy[J]. J Antimicrob Chemother, 1999,44(6) :811.
  • 4Sendi PP, Briggs AH.Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane[J].Health Econ, 2001,10(7) : 675.
  • 5Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves[J]. Bull Worm He- alth Organ, 2007,85 ( 11 ) : 833.
  • 6Sun YK, Joshua AS, Sue JG. Cost-effectiveness, afford- ability, and uncertainty[EB/OL].http ://www.chds.hsph. harvard. topic/integrating-cost-effectiv- eness-affordability-and-uncertainty.2011-09-28.
  • 7.
  • 8Bala MV,Mauskopf J.Estimating the Bayesian loss function:a conjoint analysis approach[].Intern J Technol Assess Health Care.2001
  • 9Skrepnek GH.The contrast and convergence of bayesian and frequentist statistical approaches in pharmacoeconomic analysis[].Pharmacoeconomics.2007
  • 10Kennedy,P.A Guide to Econometrics[]..1998

共引文献20

同被引文献13

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部